1. Home
  2. LOAN vs TNXP Comparison

LOAN vs TNXP Comparison

Compare LOAN & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LOAN
  • TNXP
  • Stock Information
  • Founded
  • LOAN 1989
  • TNXP 2007
  • Country
  • LOAN United States
  • TNXP United States
  • Employees
  • LOAN N/A
  • TNXP N/A
  • Industry
  • LOAN Real Estate Investment Trusts
  • TNXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • LOAN Real Estate
  • TNXP Health Care
  • Exchange
  • LOAN Nasdaq
  • TNXP Nasdaq
  • Market Cap
  • LOAN 61.4M
  • TNXP 57.9M
  • IPO Year
  • LOAN 1999
  • TNXP N/A
  • Fundamental
  • Price
  • LOAN $5.67
  • TNXP $0.24
  • Analyst Decision
  • LOAN
  • TNXP Strong Buy
  • Analyst Count
  • LOAN 0
  • TNXP 2
  • Target Price
  • LOAN N/A
  • TNXP $53.50
  • AVG Volume (30 Days)
  • LOAN 20.8K
  • TNXP 134.8M
  • Earning Date
  • LOAN 03-10-2025
  • TNXP 11-12-2024
  • Dividend Yield
  • LOAN 8.11%
  • TNXP N/A
  • EPS Growth
  • LOAN 6.53
  • TNXP N/A
  • EPS
  • LOAN 0.49
  • TNXP N/A
  • Revenue
  • LOAN $7,394,068.00
  • TNXP $11,291,000.00
  • Revenue This Year
  • LOAN N/A
  • TNXP $64.71
  • Revenue Next Year
  • LOAN N/A
  • TNXP $24.49
  • P/E Ratio
  • LOAN $11.57
  • TNXP N/A
  • Revenue Growth
  • LOAN 5.79
  • TNXP 183.05
  • 52 Week Low
  • LOAN $4.60
  • TNXP $0.12
  • 52 Week High
  • LOAN $5.90
  • TNXP $12.48
  • Technical
  • Relative Strength Index (RSI)
  • LOAN 57.76
  • TNXP 43.95
  • Support Level
  • LOAN $5.30
  • TNXP $0.22
  • Resistance Level
  • LOAN $5.70
  • TNXP $0.26
  • Average True Range (ATR)
  • LOAN 0.12
  • TNXP 0.04
  • MACD
  • LOAN 0.00
  • TNXP -0.02
  • Stochastic Oscillator
  • LOAN 74.00
  • TNXP 7.38

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: